Time series analysis of California's prescription monitoring program: impact on prescribing and multiple provider episodes.

UNLABELLED Prescription monitoring programs (PMPs) are designed to reduce medication diversion by identifying individuals obtaining the same medication from multiple providers (termed multiple provider episodes [MPEs]). This study determined whether recent changes to California's PMP influenced: 1) the extent that practitioners issue prescriptions for a variety of Schedule II opioids; and 2) the incidence of MPEs involving these opioids. Intervention time series of California's PMP data was used to determine the effect of requiring practitioners to transition from using triplicate prescription forms for Schedule II medications to security forms for all controlled substances. Outcome measures included changes in number of prescriptions issued for Schedule II long-acting or short-acting (SA) opioids and the MPEs involving these medications. Requiring a security form was associated with a sustained prescribing increase for SA hydromorphone, meperidine, and SA oxycodone; no prescribing changes were found for SA fentanyl, methadone, and SA morphine, or for any long-acting opioids. The same policy change, however, increased MPEs involving all opioids. Further effort is required to determine how California's PMP can continue to ensure availability of prescription opioids for medical use while better mitigating their diversion. PERSPECTIVE Statistical model-building was used to evaluate the influence of changes to California's prescription monitoring program. The extent that practitioners prescribe Schedule II opioids and the incidence of people receiving prescriptions from multiple providers were measured. Such research illustrates the viability of evaluating drug control program impact on prescribing practice and potential diversion behaviors.

[1]  J. L. Dahl,et al.  Trends in medical use and abuse of opioid analgesics. , 2000, JAMA.

[2]  S. Fishman,et al.  Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain. , 2004, Pain medicine.

[3]  O. Blin,et al.  Impact of a prescription monitoring program on doctor‐shopping for high dosage buprenorphine , 2009, Pharmacoepidemiology and drug safety.

[4]  K. Schulman,et al.  Geographic Variation in the Prescription of Schedule II Opioid Analgesics among Outpatients in the United States , 2006 .

[5]  A. Gilson,et al.  The burden of the nonmedical use of prescription opioid analgesics. , 2009, Pain medicine.

[6]  J. Ballantyne,et al.  Opioid dependence and addiction during opioid treatment of chronic pain , 2007, PAIN.

[7]  S. Fishman,et al.  Profiling multiple provider prescribing of opioids, benzodiazepines, stimulants, and anorectics. , 2010, Drug and alcohol dependence.

[8]  Gwilym M. Jenkins,et al.  Time series analysis, forecasting and control , 1972 .

[9]  M. Kamdar,et al.  Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, Sixth Edition , 2010 .

[10]  F. Gengo,et al.  Impact of Triplicate Prescription Program on Psychotropic Prescribing Patterns in Long-Term Care Facilities , 1992, The Annals of pharmacotherapy.

[11]  C. Bishop,et al.  The Influence of Multiple Copy Prescription Programs on Analgesic Utilization , 1996 .

[12]  Adam J. Atherly,et al.  Prescription Opioid Usage and Abuse Relationships: An Evaluation of State Prescription Drug Monitoring Program Efficacy , 2009, Substance abuse : research and treatment.

[13]  M. Reidenberg Effect of the requirement for triplicate prescriptions for benzodiazepines in New York State , 1991, Clinical pharmacology and therapeutics.

[14]  Gwilym M. Jenkins,et al.  Time series analysis, forecasting and control , 1971 .

[15]  S. Soumerai,et al.  Effects of state surveillance on new post-hospitalization benzodiazepine use. , 2003, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[16]  John Lewis,et al.  What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. , 2008, Pain medicine.

[17]  Meelee Kim,et al.  Usefulness of prescription monitoring programs for surveillance—analysis of Schedule II opioid prescription data in Massachusetts, 1996–2006 , 2010, Pharmacoepidemiology and drug safety.

[18]  S. Soumerai,et al.  A retrospective data analysis of the impact of the New York triplicate prescription program on benzodiazepine use in medicaid patients with chronic psychiatric and neurologic disorders. , 2004, Clinical therapeutics.

[19]  B. Guernsey,et al.  Effect of a triplicate prescription law on prescribing of Schedule II drugs. , 1984, American journal of hospital pharmacy.

[20]  J. Fellmeth,et al.  Medical Board of California , 1999 .

[21]  R. Shader,et al.  A Controlled Study of the Effects of State Surveillance on Indicators of Problematic and Non-Problematic Benzodiazepine Use in a Medicaid Population , 2004, International journal of psychiatry in medicine.

[22]  D. Brushwood Maximizing the Value of Electronic Prescription Monitoring Programs , 2003, Journal of Law, Medicine & Ethics.

[23]  G. Glass,et al.  Design and analysis of time-series experiments , 1975 .

[24]  Grant M. Carrow,et al.  Pain management and prescription monitoring. , 2002, Journal of pain and symptom management.

[25]  K. Lapane,et al.  Effect of Triplicate Prescription Policy on Benzodiazepine Administration in Nursing Home Residents , 2001, Pharmacotherapy.

[26]  D. McDowall,et al.  Interrupted Time Series Analysis , 1980 .

[27]  M. Weintraub,et al.  Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. , 1991, JAMA.

[28]  J. Bostwick,et al.  Taking the physician out of "physician shopping": a case series of clinical problems associated with Internet purchases of medication. , 2004, Mayo Clinic proceedings.

[29]  J. Loeser,et al.  Bonica's Management of Pain , 2001 .